Compare Sociedad Quimica y Minera S.A. Common Stock (SQM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sociedad Quimica y Minera S.A. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sociedad Quimica y Minera S.A. Common Stock trades at $61 (market cap $17.95B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Sociedad Quimica y Minera S.A. Common Stock is far larger — about 2.4× Spyre Therapeutics Inc. Common Stock's market cap, and Sociedad Quimica y Minera S.A. Common Stock pays a 3.86% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sociedad Quimica y Minera S.A. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SQM | SYRE | |
|---|---|---|
Market Cap | $17.95B | $7.52B |
Volume | 910,047 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $95.31 | $108.92 |
52-Week Low | $42.39 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $18.81B | $6.52B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQM trades at $62.83, up 0.58% today, but technical indicators signal a bearish trend with strong selling pressure. The company delivered mixed Q2 2026 earnings, beating EPS estimates with $2.31 vs. $2.03 expected, while Q1 and Q4 2025 missed expectations. Valuation metrics appear attractive with P/E of 12.93 and EV/EBITDA of 7.09, supported by strong profitability margins including 42.17% gross margin and 23.78% ROE.
Despite near-term technical weakness, SQM's fundamentals remain solid with projected revenue growth to $6.7B in 2026 and net profit margin expansion to 20.62%. The consensus price target of $92.50 suggests 47% upside potential, though lithium price volatility and recent earnings misses present execution risks. Analyst sentiment is mixed with 31% Buy ratings versus 19% Sell recommendations.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sociedad Quimica y Minera S.A. Common Stock
SQM is a mining and chemical company operating in northern Chile. Its businesses include lithium, iodine, specialty plant nutrition, potassium, solar salts, and industrial chemicals.
Read more on SQM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
